Skip to main content

Advertisement

Table 5 Results of the Poisson regression models on days of hospital/ED associated CINV events

From: Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study

Parameters Breast cancer (N = 3606) Carboplatin-treated lung cancer (N = 4497) Cisplatin-treated lung cancer (N = 1154)
  Regression coefficient (95% CI) P value Regression coefficient (95% CI) P value Regression coefficient (95% CI) P value
Age -0.0032 (-0.0219; 0.0155) 0.7354 -0.0008 (-0.0120; 0.0105) 0.8961 -0.0149 (-0.0325; 0.0027) 0.0968
CCI 0.2529 (0.0572; 0.4486) 0.0113 0.0448 (0.0087; 0.0810) 0.0151 0.0747 (0.0182; 0.1312) 0.0096
Gender (male as reference)
Female NA   -0.1815 (-0.4202; 0.0573) 0.1363 -0.0132 (-0.3975; 0.3711) 0.9463
Days with cyclophosphamide (in breast cancer) or carboplatin (in lung cancer) treatment -0.3800 (-0.5600; -0.2000) <.0001 -0.0483 (-0.0848; -0.0118) 0.0095 0.0113 (-0.0263; 0.0488) 0.5561
Antiemetic regimen (older 5-HT3 RAs as reference)
 Palonosetron -0.6431 (-1.0391; -0.2471)* 0.0015 -0.3436 (-0.5871; -0.1001)* 0.0057 -0.0373 (-0.4456; 0.3711) 0.8580
  1. * In Poisson regression, the exponential of coefficient indicates the ratio of the comparison groups in outcome. The exponential of the coefficient of antiemetic regimen (-0.6431) was 0.526 in the BC cohort, indicating the average CINV-hospitalization/ED days of palonosetron group was about 52.6% of that of the comparison group (older 5-HT3 RAs). The exponential of the coefficient of antiemetic regimen (-0.3436) was 0.709 in the LC-carboplatin cohort, indicating the average CINV-hospitalization/ED days of palonosetron group was about 70.9% of that of the comparison group (older 5-HT3 RAs).